Get the Stockscreener App
121.90
0.65%
0.79
Illumina Inc stock is traded at $121.90, with a volume of 1.13M.
It is up +0.65% in the last 24 hours and up +26.09% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$121.11
Open:
$120.21
24h Volume:
1.13M
Relative Volume:
0.68
Market Cap:
$18.74B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
15.44
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
-1.33%
1M Performance:
+26.09%
6M Performance:
+59.66%
1Y Performance:
-21.43%
1-Day Range:
$119.36
$122.08
1-Week Range:
$116.21
$126.00
52-Week Range:
$68.70
$154.43
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
121.90 | 18.51B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
572.41 | 212.64B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
209.94 | 148.81B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
708.45 | 56.99B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.74 | 41.81B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.46 | 35.91B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc. (ILMN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Illumina Inc. forming a bottoming baseJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Illumina: An Excellent Profit Margin And The Sequencing Genome Market Will Unlock Value - Seeking Alpha
Is Illumina Inc. stock safe for conservative investorsQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Developing predictive dashboards with Illumina Inc. dataQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
China to lift export ban on Illumina while keeping company on watchlist By Investing.com - Investing.com South Africa
China lifts Illumina ban, clears Pacbio’s Sequel II CNDx - BioWorld MedTech
Molecular Cytogenetics Market Worth $1.43 Billion by 2030 – Growing at a CAGR of 7.1% - Barchart.com
Key facts: Illumina Q3 2025 earnings beat estimates; export ban lifted - TradingView
Illumina says China is lifting export ban - MedTech Dive
Is Illumina Inc. stock a buy in volatile marketsQuarterly Trade Review & Community Consensus Trade Alerts - newser.com
Will Illumina Inc. stock remain a Wall Street favoriteTrade Analysis Summary & Safe Entry Point Identification - newser.com
What moving averages say about Illumina Inc.Weekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Combining machine learning predictions for Illumina Inc.Market Performance Summary & Fast Moving Stock Watchlists - newser.com
Why Illumina Inc. stock is considered a top pickJuly 2025 Intraday Action & Daily Volume Surge Signals - newser.com
Illumina Says China Removed Ban on Importing DNA Sequencers - MSN
Technical analysis overview for Illumina Inc. stockWatch List & High Accuracy Swing Entry Alerts - newser.com
Array Market (Life Science and Biotechnology Instruments) - openPR.com
Strategies to average down on Illumina Inc.Jobs Report & Free Fast Entry Momentum Trade Alerts - newser.com
Illumina welcomes lifting of China's export ban, pledges engagement for lasting solution - MLex
Candlestick signals on Illumina Inc. stock today2025 Sector Review & Consistent Profit Trading Strategies - newser.com
Momentum divergence signals in Illumina Inc. chart2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
5 Revealing Analyst Questions From Illumina’s Q3 Earnings Call - Yahoo! Finance Canada
Can Illumina’s (ILMN) Clinical Growth Offset Ongoing Regulatory Challenges in China? - Yahoo! Finance UK
Can Illumina Inc. (ILU) stock hit consensus price targetsMarket Volume Report & Daily Profit Maximizing Tips - fcp.pa.gov.br
Illumina says China lifted ban on importing DNA sequencers - Medical Buyer
Will Illumina Inc. stock benefit from automationPortfolio Risk Report & Weekly High Potential Alerts - newser.com
Should I buy Illumina Inc. (ILU) stock before earnings seasonWeekly Trading Summary & Fast Gaining Stock Reports - newser.com
China to lift export ban on Illumina while keeping company on watchlist - Investing.com
Will Illumina Inc. (ILU) stock draw ESG focused fundsMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Illumina export ban to China to be lifted (ILMN:NASDAQ) - Seeking Alpha
Illumina, Inc. Responds to Positive Updates from Chinese Ministry of Commerce - MarketScreener
Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights - Business Wire
Illumina rises after China lifts export ban, Evercore sees growth in FY26 - TradingView
Can Illumina Inc. (ILU) stock surprise with quarterly resultsPortfolio Update Summary & Free Risk Controlled Daily Trade Plans - newser.com
Illumina, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Next Capital Management LLC Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
Bryce Point Capital LLC Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $8.95 Million Position in Illumina, Inc. $ILMN - MarketBeat
Transcriptome Sequencing Market to See Competition Rise | Illumina, PerkinElmer, Sengenics - openPR.com
Standard BioTools Reports Lower Revenue And Large Q3 Loss - Finimize
Will Illumina Inc. (ILU) stock test record highs in 20252025 Biggest Moves & Real-Time Volume Triggers - newser.com
U.S. Biochips Market Set to Witness Remarkable Growth| Thermo Fisher, Illumina, Agilent Technologies, and Roche - openPR.com
South Dakota Investment Council Increases Holdings in Illumina, Inc. $ILMN - MarketBeat
Chancery Considers Reviewing Icahn's $10M Illumina Settlement - Law360
Illumina Inc. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Illumina Stock Drops Amid Barclays Caution and Growth Concerns | 2025News and Statistics - IndexBox
Illumina (ILMN) Stock Trades Down, Here Is Why - TradingView
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? - Benzinga
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.69%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):